Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer

Sun Young Oh, Nawal Wasif, Marie Carmel Garcon, Gladys Rodriguez, Muhammad Wasif Saif

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients' clinical symptoms.

Original languageEnglish (US)
Pages (from-to)676-679
Number of pages4
JournalJournal of the Pancreas
Volume14
Issue number6
StatePublished - 2013
Externally publishedYes

Fingerprint

oxaliplatin
Pancreatic Neoplasms
gemcitabine
Gastrointestinal Neoplasms
Physiologic Monitoring
Platinum
Hearing Loss
Ovarian Neoplasms
Colorectal Neoplasms

Keywords

  • Deafness
  • Hearing loss
  • Oxaliplatin
  • Pancreatic neoplasms
  • Peripheral nervous system diseases

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Oh, S. Y., Wasif, N., Garcon, M. C., Rodriguez, G., & Saif, M. W. (2013). Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. Journal of the Pancreas, 14(6), 676-679.

Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. / Oh, Sun Young; Wasif, Nawal; Garcon, Marie Carmel; Rodriguez, Gladys; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 14, No. 6, 2013, p. 676-679.

Research output: Contribution to journalArticle

Oh, SY, Wasif, N, Garcon, MC, Rodriguez, G & Saif, MW 2013, 'Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer', Journal of the Pancreas, vol. 14, no. 6, pp. 676-679.
Oh, Sun Young ; Wasif, Nawal ; Garcon, Marie Carmel ; Rodriguez, Gladys ; Saif, Muhammad Wasif. / Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. In: Journal of the Pancreas. 2013 ; Vol. 14, No. 6. pp. 676-679.
@article{c0a6b0167fdf441ea6ec8d5e1b2ecb7f,
title = "Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer",
abstract = "Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1{\%} of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients' clinical symptoms.",
keywords = "Deafness, Hearing loss, Oxaliplatin, Pancreatic neoplasms, Peripheral nervous system diseases",
author = "Oh, {Sun Young} and Nawal Wasif and Garcon, {Marie Carmel} and Gladys Rodriguez and Saif, {Muhammad Wasif}",
year = "2013",
language = "English (US)",
volume = "14",
pages = "676--679",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "6",

}

TY - JOUR

T1 - Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer

AU - Oh, Sun Young

AU - Wasif, Nawal

AU - Garcon, Marie Carmel

AU - Rodriguez, Gladys

AU - Saif, Muhammad Wasif

PY - 2013

Y1 - 2013

N2 - Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients' clinical symptoms.

AB - Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients' clinical symptoms.

KW - Deafness

KW - Hearing loss

KW - Oxaliplatin

KW - Pancreatic neoplasms

KW - Peripheral nervous system diseases

UR - http://www.scopus.com/inward/record.url?scp=84887489529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887489529&partnerID=8YFLogxK

M3 - Article

C2 - 24216561

AN - SCOPUS:84887489529

VL - 14

SP - 676

EP - 679

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 6

ER -